MCL1 and breast carcinoma: Inactivation of pERK1/2 with MEK inhibitor U0 126 (data not shown) or nitric oxide donor DETA-NONOate promoted the decline of Mcl-1 levels in breast cancer cell line MDA-MB-468 (Figure 6A).